Literature DB >> 17665973

TIM-3 as a therapeutic target in human inflammatory diseases.

David E Anderson1.   

Abstract

T-cell immunoglobulin- and mucin-domain-containing molecule-3 (Tim-3) was the first, and is presently the only, surface molecule that can specifically identify T(H)1 cells in both mice and humans. Engagement of Tim-3 by its ligand galectin-9 negatively regulates IFN-gamma secretion and influences the ability to induce T cell tolerance in both mice and man. Numerous studies have demonstrated that Tim-3 influences autoimmune diseases, including diabetes and multiple sclerosis, and its role in other inflammatory diseases including allergies and cancer is beginning to become clear.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17665973     DOI: 10.1517/14728222.11.8.1005

Source DB:  PubMed          Journal:  Expert Opin Ther Targets        ISSN: 1472-8222            Impact factor:   6.902


  12 in total

1.  T cell immunoglobulin- and mucin-domain-containing molecule 3 gene polymorphisms and susceptibility to pancreatic cancer.

Authors:  Danian Tong; Yujia Zhou; Wei Chen; Yang Deng; Lei Li; Zhenyi Jia; Dachuan Qi
Journal:  Mol Biol Rep       Date:  2012-06-26       Impact factor: 2.316

2.  Expression of Tim-3 in breast cancer tissue promotes tumor progression.

Authors:  Shiqing Cheng; Fuyan Han; Yanqiu Xu; Teng Qu; Ying Ju
Journal:  Int J Clin Exp Pathol       Date:  2018-03-01

3.  T-cell immunoglobulin- and mucin-domain-containing molecule 3 genetic variants and HIV+ non-Hodgkin lymphomas.

Authors:  Haihan Song; Shaolin Ma; Zhanshan Cha; Lei Chen; Danian Tong; Lan Ma; Weiguo Song; Jianwen Bai
Journal:  Inflammation       Date:  2013-08       Impact factor: 4.092

4.  Role of Tim-3/galectin-9 inhibitory interaction in viral-induced immunopathology: shifting the balance toward regulators.

Authors:  Sharvan Sehrawat; Amol Suryawanshi; Mitsuomi Hirashima; Barry T Rouse
Journal:  J Immunol       Date:  2009-03-01       Impact factor: 5.422

Review 5.  Cancer and pregnancy: parallels in growth, invasion, and immune modulation and implications for cancer therapeutic agents.

Authors:  Shernan G Holtan; Douglas J Creedon; Paul Haluska; Svetomir N Markovic
Journal:  Mayo Clin Proc       Date:  2009-11       Impact factor: 7.616

Review 6.  TIM-3 as a new therapeutic target in systemic lupus erythematosus.

Authors:  Hai-Feng Pan; Ning Zhang; Wen-Xian Li; Jin-Hui Tao; Dong-Qing Ye
Journal:  Mol Biol Rep       Date:  2010-01       Impact factor: 2.316

7.  Expression of TIM-3, Human β-defensin-2, and FOXP3 and Correlation with Disease Activity in Pediatric Crohn's Disease with Infliximab Therapy.

Authors:  Mi Jin Kim; Woo Yong Lee; Yon Ho Choe
Journal:  Gut Liver       Date:  2015-05-23       Impact factor: 4.519

8.  TIM-3 Suppresses Anti-CD3/CD28-Induced TCR Activation and IL-2 Expression through the NFAT Signaling Pathway.

Authors:  Brian Tomkowicz; Eileen Walsh; Adam Cotty; Raluca Verona; Nina Sabins; Fred Kaplan; Sandy Santulli-Marotto; Chen-Ni Chin; Jill Mooney; Russell B Lingham; Michael Naso; Timothy McCabe
Journal:  PLoS One       Date:  2015-10-22       Impact factor: 3.240

9.  Galectin-9 induced myeloid suppressor cells expand regulatory T cells in an IL-10-dependent manner in CVB3-induced acute myocarditis.

Authors:  Yingying Zhang; Li Jiang; Mengying Zhang; Kun Lv
Journal:  Int J Mol Sci       Date:  2014-02-25       Impact factor: 5.923

10.  Increased expression of T cell immunoglobulin and mucin domain 3 aggravates brain inflammation via regulation of the function of microglia/macrophages after intracerebral hemorrhage in mice.

Authors:  ChangJun Xu; Tao Wang; Si Cheng; YuGuang Liu
Journal:  J Neuroinflammation       Date:  2013-12-01       Impact factor: 8.322

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.